US FDA to establish timeframes for drug companies to implement new safety labelling
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is seeking feedback on its plans to establish general timeframes within which new safety labelling for approved prescription drugs should be disseminated and reflected on a product's packaging1.